Rigel Pharma (RIGL) Posts Smaller than Expected Q3 Loss
Get Alerts RIGL Hot Sheet
Price: $1.08 +2.86%
Revenue Growth %: +21.1%
Financial Fact:
Interest income: 110K
Today's EPS Names:
MAXN, CSTR, ACU, More
Revenue Growth %: +21.1%
Financial Fact:
Interest income: 110K
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q3 EPS of ($0.24), $0.03 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $0 versus the consensus estimate of $430 thousand.
As of September 30, 2014, Rigel had cash, cash equivalents and available for sale securities of $157.7 million, compared to $212.0 million as of December 31, 2013. Rigel expects to end 2014 with cash and investments in excess of $135.0 million, which is expected to be sufficient to fund operations into the third quarter of 2016.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Growth isn't weak enough to truly undercut inflation pressures - BMO
- 'A moment of truth' for Tesla and Musk is here - Wedbush
- Wells Fargo on Super Micro Computer (SMCI): 'No Positive Preannouncement
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!